Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-108887
Filing Date
2025-08-14
Accepted
2025-08-14 16:15:51
Documents
47
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q tcrt-20250630.htm   iXBRL 10-Q 1510201
2 EX-31.1 tcrt-ex31_1.htm EX-31.1 14159
3 EX-32.1 tcrt-ex32_1.htm EX-32.1 7831
  Complete submission text file 0000950170-25-108887.txt   5522108

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT tcrt-20250630.xsd EX-101.SCH 1021073
49 EXTRACTED XBRL INSTANCE DOCUMENT tcrt-20250630_htm.xml XML 597748
Mailing Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005
Business Address 2617 BISSONNET ST SUITE 233 HOUSTON TX 77005 (346) 355-4099
Alaunos Therapeutics, Inc. (Filer) CIK: 0001107421 (see all company filings)

EIN.: 841475642 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33038 | Film No.: 251219362
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)